ArticleMolecular medicine (Cambridge, Mass.)2026
TAX1BP1 protects against doxorubicin-induced cardiotoxicity via maintaining mitochondrial function in a mTORC2-SGK1-VDAC1 manner.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Therapeutic Potential of Stem Cell Therapy for Doxorubicin-Induced Cardiotoxicity: A Narrative Review.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe efficacy of doxorubicin (DOX) in treating various cancers is hindered by its associated cardiotoxicity, limiting its clinical utility. Mitophagy dysfunction and impaired mitochondrial function may be significantly involved in the development of DOX-induced cardiotoxicity (DIC). Tax1 (T-cell leukemia virus type I)-binding protein 1 (TAX1BP1) is an autophagic receptor; however, its role in DIC remains elusive. Therefore, the objective of this study was to assess the influence of TAX1BP1 overexpression on DIC and its molecular mechanisms, focusing specifically on mPTP opening and mitophagy in cardiomyocytes.
methodsMale C57BL/6J mice were intravenously administered recombinant adeno-associated virus serotype-9 (AAV9) carrying Flag-TAX1BP1 and cardiac troponin T (cTNT) promoter (AAV9-cTNT-TAX1BP1). Mice were randomly subjected to a DOX challenge with weekly administration of 4 mg/kg body weight for 5 weeks.
resultsTAX1BP1 levels were notably decreased in the cardiac tissues of DIC mice. Cardiac TAX1BP1 overexpression alleviated cardiac remodeling and dysfunction in mice with DIC, with little effect from TAX1BP1 overexpression alone. TAX1BP1 overexpression improved mitochondrial dysfunction and promoted mitophagy in DIC cardiomyocytes. Furthermore, TAX1BP1 interacted with mTOR through its SKICH domain and facilitated the assembly of the mTORC2 complex, thereby initiating SGK1 phosphorylation, limiting the aggregation of VDAC1 and preventing the opening of the mitochondrial permeability transition pore (mPTP) in the cardiomyocytes facing DOX challenge.
conclusionCollectively, our study highlights the significant role of TAX1BP1 in preventing mPTP opening and enhancing mitophagy, which contributes to the mitigation of mitochondrial and cardiac abnormalities associated with DIC. Our findings highlighted the potential therapeutic benefits of targeting TAX1BP1 in patients with DIC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.